What is Candel Therapeutics, Inc.'s stock issuance proceeds?

Candel Therapeutics, Inc. (CADL) reported stock issuance proceeds of $28K in Q1 2026.

How has Candel Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?

Candel Therapeutics, Inc.'s stock issuance proceeds decreased by 92.7% year-over-year, from $384K to $28K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Candel Therapeutics, Inc. CADL Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Gilead SciencesGILD

$166M-34.1%

Replimune GroupREPL

$791K-99.3%

CG OncologyCGON

$391.55M+57,312%

Immix Biopharma, Inc.IMMX

$33.53K—

CytomX TherapeuticsCTMX

$228.35M—

RegenxbioRGNX

$146K-2.7%

Other financials

Income statement

See full

Revenue$31.0K0.0%

Operating income-$16.3M-100%

Net income-$8.9M-220%

EPS (diluted)-$0.14-208%

Balance sheet

See full

Cash & equivalents$194.8M+111%

Total debt$2.8M-73.9%

Total equity$138.0M+84.8%

Total assets$201.9M+111%

Cash flow

See full

Operating cash flow-$18.0M-109%

CapEx$675.0K+22,400%

Free cash flow-$18.7M-117%

Valuation

See full

Market cap$693.87M+192%

Enterprise value$501.88M+220%

P/S5,595.7×-18,674×

Profitability

See full

Operating margin-28,000.8%+15,050pp

Net margin-15,156.5%-5,064pp

FCF margin-26,383.9%+14,851pp

Returns & leverage

See full

Return on equity-51.2%-16.6pp

Debt / equity0×-0.1×

Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s stock issuance proceeds?: Candel Therapeutics, Inc. (CADL) reported stock issuance proceeds of $28K in Q1 2026.
How has Candel Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?: Candel Therapeutics, Inc.'s stock issuance proceeds decreased by 92.7% year-over-year, from $384K to $28K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.